Tumores de Cabeça e Pescoço
Estudo randomizado | Efeito da terapia de manutenção com capecitabina aliada ao melhor cuidado de suporte vs. melhor cuidado de suporte isoladamente na sobrevida livre de progressão entre pacientes com carcinoma nasofaríngeo metastático recém-diagnosticado que receberam quimioterapia de indução.
28 Abr, 2022 | 11:51hEffect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
Randomized trial of efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma demonstrates that capecitabine maintenance therapy improved survival & was associated with manageable toxicities. https://t.co/Ay2WZ7ZuCN pic.twitter.com/sZJ6qfzCOY
— JAMA Oncology (@JAMAOnc) February 17, 2022
Estudo randomizado | Sintilimabe vs. placebo em combinação com quimioterapia como tratamento de primeira linha para carcinoma esofágico de células escamosas metastático ou localmente avançado.
21 Abr, 2022 | 12:13h
Comentário no Twitter
Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu
— The BMJ (@bmj_latest) April 19, 2022
Desenvolvimento e validação de modelos de aprendizado de máquina (machine learning) para prever metástases nodais ocultas no carcinoma de células escamosas da cavidade oral em estágio inicial.
21 Abr, 2022 | 12:01h
Comentário no Twitter
In this diagnostic modeling study, #MachineLearning models built with multi-institutional data showed potential to reduce morbidity from elective neck dissections with similar cancer outcomes in patients with early-stage oral cavity squamous cell carcinoma https://t.co/aRktgc0ms6
— JAMA Network Open (@JAMANetworkOpen) April 13, 2022
Desenvolvimento e validação de um modelo de decisão analítica para vigilância pós-tratamento de pacientes com carcinoma orofaríngeo.
18 Abr, 2022 | 14:55hEstudo randomizado | Efeito da quimioterapia de indução com paclitaxel, cisplatina e capecitabina vs. cisplatina e fluorouracil na sobrevida livre de recorrência para pacientes com carcinoma nasofaríngeo estágios IVA a IVB.
29 Mar, 2022 | 13:49hEffect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)
Comentário: Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma — Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
Phase 3 randomized trial of paitents with stage IVA to IVB nasopharyngeal carcinoma shows that induction chemotherapy w 2 cycles of paclitaxel/cisplatin/capecitabine improved failure-free survival vs. cisplatin/5-FU before concurrent chemoradiation. https://t.co/YYEvFsTxgd pic.twitter.com/7qbSXLWCE1
— JAMA Oncology (@JAMAOnc) March 24, 2022
Diretrizes clínicas da SEOM-TTCC para câncer de nasofaringe.
25 Mar, 2022 | 15:15hSEOM-TTCC clinical guideline in nasopharynx cancer (2021) – Clinical and Translational Oncology
Tendências de tumores associados ao HPV, características demográficas e vacinação nos EUA, 2001-2017.
17 Mar, 2022 | 12:46hEntrevista com o autor: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations
Conteúdos relacionados:
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
Estudo randomizado | Em pacientes com câncer de tireoide de baixo risco, a tireoidectomia sem ablação por radioiodo foi não inferior à tireoidectomia com ablação por radioiodo em 3 anos.
10 Mar, 2022 | 15:57hThyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: New research casts doubt on a cornerstone of thyroid cancer treatment – STAT
Comentário no Twitter
In RCT involving patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve the use of radioiodine was noninferior to the use of radioiodine in the response to treatment at 3 years. https://t.co/RaJL3tdE4T pic.twitter.com/8nIPw50nkg
— NEJM (@NEJM) March 9, 2022
Estudo randomizado | Irradiação eletiva na parte superior do pescoço não envolvido vs. no pescoço inteiro para pacientes com carcinoma nasofaríngeo.
9 Mar, 2022 | 13:17hElective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentários:
Elective Upper-Neck vs Whole-Neck Irradiation in Nasopharyngeal Carcinoma – The ASCO Post
Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma— Phase III trial also shows that upper-neck irradiation leads to fewer late toxicities – MedPage Today (link para o resumo – $ para o texto completo)
Estudo randomizado | Em pacientes com câncer de cabeça e pescoço submetidos a cirurgia, a quimioterapia com cisplatina semanal é não inferior à cisplatina a cada 3 semanas e está associada com toxicidade reduzida.
3 Mar, 2022 | 15:41h
Comentário do autor no Twitter
Dear friends,
Finally, the results of JCOG1008, post operative CRT (weekly CDDP vs. 3-weekly CDDP) has published on Journal of Oncology.
Weekly CDDP+RT is a new treatment option with equal efficacy and better safety profile.
Please check the manuscript!!https://t.co/XG6mkGeo4Y— Naomi Kiyota, MD, PhD (@kiyota_naomi) March 1, 2022